176 related articles for article (PubMed ID: 16892433)
1. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.
Fuchs S; Dib N; Cohen BM; Okubagzi P; Diethrich EB; Campbell A; Macko J; Kessler PD; Rasmussen HS; Epstein SE; Kornowski R
Catheter Cardiovasc Interv; 2006 Sep; 68(3):372-8. PubMed ID: 16892433
[TBL] [Abstract][Full Text] [Related]
2. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Hedman M; Hartikainen J; Syvänne M; Stjernvall J; Hedman A; Kivelä A; Vanninen E; Mussalo H; Kauppila E; Simula S; Närvänen O; Rantala A; Peuhkurinen K; Nieminen MS; Laakso M; Ylä-Herttuala S
Circulation; 2003 Jun; 107(21):2677-83. PubMed ID: 12742981
[TBL] [Abstract][Full Text] [Related]
4. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina.
Briguori C; Reimers B; Sarais C; Napodano M; Pascotto P; Azzarello G; Bregni M; Porcellini A; Vinante O; Zanco P; Peschle C; Condorelli G; Colombo A
Am Heart J; 2006 Mar; 151(3):674-80. PubMed ID: 16504630
[TBL] [Abstract][Full Text] [Related]
5. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route.
Baldazzi F; Jørgensen E; Ripa RS; Kastrup J
Eur Heart J; 2008 Aug; 29(15):1819-26. PubMed ID: 18524811
[TBL] [Abstract][Full Text] [Related]
6. Release of cardiac biochemical markers after percutaneous myocardial laser or sham procedures.
Salem M; Rotevatn S; Stavnes S; Brekke M; Pettersen R; Kuiper K; Ulvik R; Nordrehaug JE
Int J Cardiol; 2005 Sep; 104(2):144-51. PubMed ID: 16168806
[TBL] [Abstract][Full Text] [Related]
7. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.
Rutanen J; Rissanen TT; Markkanen JE; Gruchala M; Silvennoinen P; Kivelä A; Hedman A; Hedman M; Heikura T; Ordén MR; Stacker SA; Achen MG; Hartikainen J; Ylä-Herttuala S
Circulation; 2004 Mar; 109(8):1029-35. PubMed ID: 14967735
[TBL] [Abstract][Full Text] [Related]
9. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
Rajagopalan S; Mohler E; Lederman RJ; Saucedo J; Mendelsohn FO; Olin J; Blebea J; Goldman C; Trachtenberg JD; Pressler M; Rasmussen H; Annex BH; Hirsch AT;
Am Heart J; 2003 Jun; 145(6):1114-8. PubMed ID: 12796772
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).
Tse HF; Thambar S; Kwong YL; Rowlings P; Bellamy G; McCrohon J; Thomas P; Bastian B; Chan JK; Lo G; Ho CL; Chan WS; Kwong RY; Parker A; Hauser TH; Chan J; Fong DY; Lau CP
Eur Heart J; 2007 Dec; 28(24):2998-3005. PubMed ID: 17984132
[TBL] [Abstract][Full Text] [Related]
11. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
Pelliccia F; Pasceri V; Marazzi G; Rosano G; Greco C; Gaudio C
Am Heart J; 2012 Jun; 163(6):1019-23. PubMed ID: 22709755
[TBL] [Abstract][Full Text] [Related]
12. VEGF gene transfer for diabetic neuropathy.
Isner JM; Ropper A; Hirst K
Hum Gene Ther; 2001 Aug; 12(12):1593-4. PubMed ID: 11529248
[TBL] [Abstract][Full Text] [Related]
13. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease.
Ripa RS; Wang Y; Jørgensen E; Johnsen HE; Hesse B; Kastrup J
Eur Heart J; 2006 Aug; 27(15):1785-92. PubMed ID: 16825290
[TBL] [Abstract][Full Text] [Related]
14. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
Losordo DW; Schatz RA; White CJ; Udelson JE; Veereshwarayya V; Durgin M; Poh KK; Weinstein R; Kearney M; Chaudhry M; Burg A; Eaton L; Heyd L; Thorne T; Shturman L; Hoffmeister P; Story K; Zak V; Dowling D; Traverse JH; Olson RE; Flanagan J; Sodano D; Murayama T; Kawamoto A; Kusano KF; Wollins J; Welt F; Shah P; Soukas P; Asahara T; Henry TD
Circulation; 2007 Jun; 115(25):3165-72. PubMed ID: 17562958
[TBL] [Abstract][Full Text] [Related]
15. Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting.
Murakami M; Iwasaki K; Kusachi S; Hina K; Hirota M; Hirohata S; Kamikawa S; Sangawa M; Yamamoto K; Shiratori Y
Int J Cardiol; 2006 Feb; 107(1):48-53. PubMed ID: 16337497
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
Stewart DJ; Hilton JD; Arnold JM; Gregoire J; Rivard A; Archer SL; Charbonneau F; Cohen E; Curtis M; Buller CE; Mendelsohn FO; Dib N; Page P; Ducas J; Plante S; Sullivan J; Macko J; Rasmussen C; Kessler PD; Rasmussen HS
Gene Ther; 2006 Nov; 13(21):1503-11. PubMed ID: 16791287
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.
Povsic TJ; Losordo DW; Story K; Junge CE; Schatz RA; Harrington RA; Henry TD
Am Heart J; 2012 Nov; 164(5):689-697.e3. PubMed ID: 23137499
[TBL] [Abstract][Full Text] [Related]
18. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study.
Banai S; Ben Muvhar S; Parikh KH; Medina A; Sievert H; Seth A; Tsehori J; Paz Y; Sheinfeld A; Keren G
J Am Coll Cardiol; 2007 May; 49(17):1783-9. PubMed ID: 17466229
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris.
Pelliccia F; Pasceri V; Granatelli A; Pristipino C; Speciale G; Roncella A; Cianfrocca C; Mercuro G; Richichi G
Am J Cardiol; 2006 Dec; 98(11):1461-3. PubMed ID: 17126650
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
